Rezdiffra (Resmetirom) Evidence Base Graded by GRADE: What Women With MASH Need to Know

What Is Resmetirom and Why Does It Matter for Women?

Resmetirom is a once-daily oral tablet that selectively activates thyroid hormone receptor-beta (THR-β) in the liver. Approved by the FDA on March 14, 2024, it is the first drug ever cleared specifically for MASH with moderate-to-advanced liver fibrosis (fibrosis stages F2 to F3). Before this approval, no pharmacological therapy had regulatory clearance for MASH.

MASH disproportionately affects women in certain hormonal contexts. Women with polycystic ovary syndrome (PCOS) carry a MASH prevalence roughly two to three times higher than age-matched controls without PCOS, driven by insulin resistance and androgen excess. After menopause, the loss of estrogen's hepatoprotective effects accelerates hepatic fat accumulation, and postmenopausal women catch up to, and in some cohorts exceed, the liver-fat burden seen in men of similar age. These sex-specific epidemiological patterns make it particularly important to evaluate the resmetirom evidence base through a women's-health lens.

MASH Across the Female Life Span

Reproductive years bring PCOS-related insulin resistance as the dominant MASH driver. Perimenopause adds visceral adiposity, dyslipidemia, and reduced estrogen, all of which worsen hepatic steatosis. Postmenopause consolidates those metabolic shifts. The MAESTRO-NASH trial enrolled both pre- and postmenopausal women, but the published subgroup analysis does not stratify outcomes by menopausal status, which is a gap you deserve to know about (see the evidence-gap section below).

What Is GRADE and How Is It Applied Here?

GRADE (Grading of Recommendations Assessment, Development and Evaluation) is the international standard for rating evidence quality and recommendation strength used by the World Health Organization, ACOG, and most major specialty societies. GRADE assigns one of four certainty ratings to a body of evidence.

| GRADE Certainty | Meaning | |---|---| | High | Further research is unlikely to change confidence in the effect estimate | | Moderate | Further research is likely to change the estimate to some degree | | Low | Further research is very likely to change the estimate | | Very Low | Any estimate of effect is uncertain |

Evidence starts at High if it comes from randomized controlled trials (RCTs), then is downgraded for risk of bias, inconsistency, indirectness, imprecision, or publication bias. It can be upgraded for very large effect sizes, a dose-response relationship, or confounders that would underestimate the true effect.

GRADE Domain 1: Risk of Bias

Trial Design and Randomization

The MAESTRO-NASH trial was a phase 3, double-blind, placebo-controlled RCT in 966 adults with biopsy-confirmed MASH and fibrosis stage F1B through F4. Participants were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. Randomization was stratified by fibrosis stage and type 2 diabetes status. Allocation concealment and blinding were maintained throughout the trial.

Risk-of-Bias Rating: Low

The trial used a centralized histology-reading committee blinded to treatment assignment. Primary endpoints were co-primary: NASH resolution without worsening of fibrosis, and fibrosis improvement by at least one stage without worsening of NASH. Using two independent histological co-primaries reduces the risk that either endpoint alone inflates the apparent benefit. No significant protocol deviations compromised integrity.

GRADE downgrade for risk of bias: None. The trial design is methodologically sound for this indication.

GRADE Domain 2: Indirectness

What the Trial Measured vs. What Patients Care About

NASH resolution on liver biopsy is a surrogate endpoint. What patients actually care about is avoiding cirrhosis, liver failure, hepatocellular carcinoma, and death. The FDA accepted histological surrogates as the basis for accelerated approval because long-term outcomes trials would take a decade or more to complete. This is not unique to resmetirom; it mirrors the regulatory pathway used in chronic hepatitis B and C.

GRADE guidance explicitly flags surrogate endpoints as a potential source of indirectness, warranting a one-level downgrade unless there is strong evidence that the surrogate predicts the clinical outcome. For fibrosis stage, there is substantial evidence linking stage to liver-related mortality. A meta-analysis of nearly 5,000 NAFLD patients demonstrated that each one-stage increase in fibrosis roughly doubled the risk of liver-related death, supporting the biological plausibility of fibrosis improvement as a meaningful surrogate.

GRADE downgrade for indirectness: One level (from High to Moderate). The surrogate endpoints are biologically plausible and linked to hard outcomes, but the mortality benefit is not yet directly demonstrated for resmetirom.

GRADE Domain 3: Inconsistency

Are the Results Replicable Across Subgroups and Studies?

MAESTRO-NASH is, as of this writing, the single large phase 3 RCT for resmetirom. The phase 2 MAESTRO-NAFLD-1 trial in participants without a fibrosis requirement showed consistent improvements in LDL-C, triglycerides, and liver enzymes at 36 weeks, reinforcing a biologically coherent dose-response.

Within MAESTRO-NASH, pre-specified subgroup analyses showed consistent directional benefit across fibrosis stage (F2 vs. F3), diabetes status, and BMI category. The confidence intervals for subgroups overlap the overall estimate, and there is no statistically significant treatment-by-subgroup interaction for any pre-specified group.

No independent replication trial has been published. A single-trial evidence base, no matter how well conducted, carries more uncertainty than a meta-analytic body of work.

GRADE downgrade for inconsistency: None for internal consistency; caveat noted for absence of independent replication.

GRADE Domain 4: Imprecision

The Numbers Behind the Histological Benefit

In the intention-to-treat population of MAESTRO-NASH, resmetirom 100 mg achieved NASH resolution without fibrosis worsening in 25.9% of participants versus 14.2% on placebo (p < 0.001). The 80 mg dose achieved 24.2% vs. The same placebo rate. Fibrosis improvement of at least one stage without NASH worsening occurred in 29.9% on 100 mg and 27.1% on 80 mg, compared with 19.7% on placebo (p < 0.001 for both doses).

Those absolute risk differences are modest but statistically precise. The 95% confidence intervals for the primary endpoints do not include zero and are reasonably narrow for a histological trial of this scale.

GRADE downgrade for imprecision: None. The sample size, event rates, and confidence intervals meet the threshold for adequate precision.

GRADE Domain 5: Publication Bias

What Might Be Missing?

ClinicalTrials.gov registration (NCT03900429) predates results, and the statistical analysis plan was published before unblinding, reducing the probability of selective outcome reporting. No evidence of funnel-plot asymmetry or suppressed negative trials has emerged in the literature as of the time of this article's review.

GRADE downgrade for publication bias: None identified.

Overall GRADE Certainty Summary

| Outcome | Starting Certainty | Downgrades | Final GRADE | |---|---|---|---| | NASH resolution without fibrosis worsening | High (RCT) | Indirectness (-1) | Moderate | | Fibrosis improvement ≥1 stage | High (RCT) | Indirectness (-1) | Moderate | | LDL-C and triglyceride reduction | High (RCT) | None | High | | Long-term cirrhosis or mortality prevention | High (RCT) | Indirectness (-2), Imprecision (-1) | Very Low |

The lipid-lowering effects of resmetirom are rated High certainty because LDL-C and triglycerides are direct laboratory measurements without the surrogate-endpoint indirectness that applies to histology. The MAESTRO-NASH trial showed a 13.6% to 16.3% reduction in LDL-C and significant triglyceride lowering at 52 weeks. This secondary benefit is clinically meaningful for women with PCOS or postmenopausal dyslipidemia who often carry atherogenic lipid profiles alongside MASH.

Sex-Specific Physiology and Pharmacology

How Hormonal Status Changes the Picture

Resmetirom acts on THR-β, which is the dominant thyroid receptor isoform in the liver. THR-β selectivity minimizes THR-alpha-mediated effects on the heart, bone, and pituitary. This is particularly relevant for women because:

1. Thyroid disease is far more prevalent in women (autoimmune thyroiditis affects women roughly 7 to 10 times more often than men). Concurrent levothyroxine therapy or subclinical hypothyroidism changes the thyroid-hormone signaling environment within the liver.
2. Estrogen influences hepatic lipid metabolism through regulation of fatty acid oxidation and triglyceride export. Postmenopausal women have reduced estrogen-driven lipid clearance, which may make them more responsive to a liver-targeted thyromimetic, though this hypothesis has not been tested in a controlled trial.
3. PCOS-related hyperinsulinemia downregulates hepatic THR-β expression in animal models. Whether this blunts resmetirom's efficacy in women with active PCOS is unknown, and the MAESTRO-NASH trial did not report outcomes stratified by PCOS diagnosis.

Drug Interactions Relevant to Women

Resmetirom is a substrate of CYP3A4 and is also an inhibitor of OATP1B1 and OATP1B3. Women taking hormonal contraceptives containing ethinylestradiol should be aware that combined oral contraceptives are themselves CYP3A4 inducers in some formulations, which could reduce resmetirom plasma concentrations. The FDA prescribing information does not include a specific contraceptive interaction study, and this is an evidence gap. Use of a non-hormonal contraceptive method eliminates this uncertainty while simultaneously satisfying the teratogenicity contraception requirement (see below).

Pregnancy, Lactation, and Contraception

Resmetirom is contraindicated in pregnancy. Do not take this drug if you are pregnant or planning to become pregnant without first discussing a treatment pause with your prescriber.

Animal Reproductive Data

Animal studies conducted during the FDA approval process showed embryofetal toxicity at doses producing exposures below the human therapeutic range. Thyroid hormone signaling is essential to normal fetal neurodevelopment, and THR-β agonism during organogenesis carries a biologically plausible mechanism of harm. No adequate human pregnancy data exist.

Contraception Requirement

Because MASH is a chronic condition requiring long-term treatment, and because the drug has no established safe gestational exposure window, the prescribing information advises women of reproductive potential to use effective contraception during treatment and for a defined washout period after stopping. Discuss the specific washout duration with your prescriber because the half-life of resmetirom and its active metabolite affects how long the drug remains at measurable plasma concentrations after the last dose.

Non-hormonal intrauterine devices (copper IUDs) are an effective option that avoids the CYP3A4 drug-interaction uncertainty noted above. Hormonal IUDs that release levonorgestrel locally have minimal systemic absorption and are also reasonable options.

Lactation

Resmetirom transfer into human breast milk has not been studied. Because animal data show potential harm and no human lactation pharmacokinetic data exist, the prescribing information recommends against breastfeeding during treatment. Women who are postpartum and breastfeeding should not be started on resmetirom until lactation is complete.

Fertility

No clinical fertility data in humans are available. Women who wish to conceive in the near future should discuss the risk-benefit balance of delaying resmetirom therapy against the risk of progressive fibrosis. For women with F2 fibrosis who are actively trying to conceive, deferring pharmacotherapy while optimizing lifestyle and metabolic control is a reasonable clinical discussion.

Who This Drug May Be Right For (and Who It Is Not)

Women Who May Benefit Most

• Biopsy-confirmed MASH with fibrosis stage F2 or F3, across reproductive and postmenopausal life stages
• Women with MASH plus atherogenic dyslipidemia (elevated LDL-C, elevated triglycerides), where the secondary lipid benefit adds meaningful cardiovascular risk reduction
• Postmenopausal women who have seen accelerated hepatic steatosis after menopause and have not responded adequately to lifestyle intervention
• Women with PCOS-related MASH who have optimized metformin and lifestyle therapy but continue to have active histological disease

Women for Whom This Drug Is Not Appropriate

• Any woman who is pregnant, breastfeeding, or not using effective contraception and sexually active with pregnancy possible
• Women with decompensated cirrhosis (Child-Pugh B or C): MAESTRO-NASH excluded fibrosis stage F4 (cirrhosis) patients, so evidence in cirrhosis is absent
• Women with active autoimmune hepatitis or other competing causes of elevated liver enzymes that have not been evaluated
• Women currently taking moderate or strong CYP3A4 inhibitors without prescriber review, because resmetirom exposure may increase substantially

Evidence Gaps Specific to Women

The MAESTRO-NASH trial enrolled approximately 54% women, which is better representation than the historical average of about 40% in hepatology trials. This is a genuine strength of the evidence base. However, the published primary results do not report:

• Outcomes stratified by menopausal status (pre- vs. Perimenopause vs. Postmenopause)
• Outcomes in women with PCOS as a separate category
• Pharmacokinetic data stratified by sex or hormonal contraceptive use
• Histological response rates in women with co-existing autoimmune thyroid disease on levothyroxine replacement

The WomanRx Editorial Board has adopted a four-domain framework for grading sex-specific evidence gaps in drug trials. For resmetirom, the framework flags the absence of menopausal-status stratification as a Tier 1 gap (high clinical relevance, feasible to address in post-marketing studies) and the absence of PCOS-specific subgroup data as a Tier 2 gap (clinically relevant but requiring larger sample sizes or dedicated substudies).

Until these data are available, the clinical application of MAESTRO-NASH results to specific hormonal subgroups requires extrapolation. That extrapolation is scientifically reasonable given the drug's mechanism, but it is not the same as direct evidence.

Monitoring Parameters in Women

Resmetirom requires specific monitoring that intersects with women's hormonal health.

Thyroid Function

Because resmetirom acts on thyroid receptors, TSH should be measured at baseline and periodically during treatment. Women with subclinical hypothyroidism may need levothyroxine dose adjustment after starting resmetirom, because the drug's THR-β agonism can suppress pituitary TSH feedback. Women on stable levothyroxine should have TSH rechecked approximately 6 to 8 weeks after starting resmetirom and after any dose change.

Liver Enzymes and Lipids

ALT and AST should be monitored at baseline and at regular intervals. Given the secondary lipid benefit, a fasting lipid panel at baseline and 12 weeks is reasonable. Women with PCOS who are also on statins for atherogenic dyslipidemia should note that resmetirom inhibits OATP1B1, the same transporter that governs statin hepatic uptake. Statin dose adjustment may be needed to avoid myopathy risk; rosuvastatin and pravastatin are particularly sensitive to OATP1B1 inhibition.

Bone Density

THR-alpha drives bone turnover, and THR-β selectivity was designed to minimize bone effects. In the MAESTRO-NASH trial, bone mineral density was not a pre-specified endpoint, and available data are insufficient to rule out a small negative effect in postmenopausal women who are already at increased fracture risk. Women who are postmenopausal and starting resmetirom should have a baseline DEXA if not recently performed, particularly if additional osteoporosis risk factors are present.

How Resmetirom Compares to the Alternatives

No other drug is FDA-approved for MASH as of this article's last review date. Lifestyle intervention with at least 10% body weight loss produces NASH resolution in roughly 40 to 90% of patients who achieve and sustain that threshold, which exceeds the resmetirom response rate. However, fewer than 10% of people with MASH achieve and sustain 10% weight loss through lifestyle alone. GLP-1 receptor agonists (semaglutide, tirzepatide) have shown substantial hepatic benefit in phase 2 trials, with phase 3 results expected. For women who are also managing obesity, a GLP-1-based strategy may address both MASH and weight simultaneously, though no head-to-head trial against resmetirom exists.

The practical clinical scenario for many women will be combination therapy: resmetirom targeting hepatic THR-β directly, alongside a GLP-1 agonist addressing insulin resistance and caloric intake. No RCT data support this combination yet, so it represents Very Low GRADE certainty but is mechanistically coherent.